Presentation Title: “New medicine technology and risk distribution”

Abstract:

Risk-benefit assessment is widely located in standard procedure for securing an ethicality of clinical research. It compares ratio between benefit and risk, and emphasis on scale of benefit. But it has not been sufficiently addressed various research about the legitimacy of high risk and risk sharing. For example, to overwhelm Pandemic, Human Challenge Trial (HCT) is considered meaningful and selectable trial type as for other individuals and humankind, even though it effects participants on low benefit-high risk. (Nir eyal et al, 2020)

 Ulrich Beck insist that modern society has produced unpredictable risk, so how to distribute risk is concerned profoundly.(Risk Society, 1992) In uncertain real world and on the nature of research, we cannot avoid various high risk-low benefit research like that big data research has a probability of exposure personal information, xenotransplantation involves a tragic hazard zoonosis.

 The purpose of this research is cope with the legitimacy of risk of medicine technology. This research shows that (i) the condition for “informed consent in uncertain risk” (individual dimension). Strictly, the clinical research participants cannot be gotten benefit through clinical research. Rather their risk accompanies inevitable and unconditional, but benefit is intermittent and incidental. Then searching (ii) social assent to risk and its fair/unfair distribution (lawful and social dimension). Who can exert the distribution authority that is important issue to this phase. Third, we examine (iii) benefit of the minority vs. risk of the majority through the zoonosis problem of xenotransplantation. In the end, we discuss how risk sharing is ethical and fair.